MCID: NSP012
MIFTS: 66

Nasopharyngeal Carcinoma

Categories: Genetic diseases, Rare diseases, Cancer diseases, Respiratory diseases, Gastrointestinal diseases

Aliases & Classifications for Nasopharyngeal Carcinoma

MalaCards integrated aliases for Nasopharyngeal Carcinoma:

Name: Nasopharyngeal Carcinoma 54 12 50 56 29 52 69
Malignant Neoplasm of Nasopharynx 12 69
Nasopharyngeal Neoplasms 42 69
Nasopharynx Carcinoma 12 14
Malignant Neoplasm of Other Specified Sites of Nasopharynx 12
Primary Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx Nos 12
Malignant Neoplasm of Posterior Wall of Nasopharynx 12
Malignant Neoplasm of Anterior Wall of Nasopharynx 12
Malignant Neoplasm of Superior Wall of Nasopharynx 12
Malignant Neoplasm of Lateral Wall of Nasopharynx 12
Malignant Tumor of Posterior Wall of Nasopharynx 12
Malignant Tumor of Anterior Wall of Nasopharynx 12
Malignant Tumor of Lateral Wall of Nasopharynx 12
Malignant Neoplasm of Nasopharyngeal Wall Nos 12
Malignant Neoplasm of Nasopharynx [ambiguous] 12
Malignant Neoplasm of Nasopharyngeal Wall 12
Malignant Neoplasm of Roof of Nasopharynx 12
Malignant Nasopharyngeal Tumor 12
Carcinoma of Nasopharynx 12
Nasopharyngeal Cancer 50
Cancer of Nasopharynx 69
Nasopharynx Cancer 12

Characteristics:

Orphanet epidemiological data:

56
nasopharyngeal carcinoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe); Age of onset: All ages;

HPO:

32
nasopharyngeal carcinoma:
Inheritance polygenic inheritance


Classifications:

Orphanet: 56  
Rare respiratory diseases


External Ids:

OMIM 54 607107
Disease Ontology 12 DOID:9261
MeSH 42 D009303
NCIt 47 C9321
Orphanet 56 ORPHA150
MESH via Orphanet 43 C538339
UMLS via Orphanet 70 C2931822 C0153392 C0238301
ICD10 via Orphanet 34 C11.0 C11.1 C11.2 more
SNOMED-CT via HPO 65 126680004

Summaries for Nasopharyngeal Carcinoma

OMIM : 54
Nasopharyngeal carcinoma (NPC, NPCA) is a multifactorial malignancy associated with both genetic and environmental factors. The cancer arises from the epithelium of the nasopharynx. The Epstein-Barr virus has been implicated (Tse et al., 2009). (607107)

MalaCards based summary : Nasopharyngeal Carcinoma, also known as malignant neoplasm of nasopharynx, is related to lung cancer and nasopharyngeal carcinoma 3, and has symptoms including neoplasia of the nasopharynx, headache and rhinorrhea. An important gene associated with Nasopharyngeal Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Apoptosis Pathway. The drugs Cisplatin and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lung, skin and liver, and related phenotypes are endocrine/exocrine gland and immune system

Disease Ontology : 12 A pharynx cancer that is located in the nasopharynx, the uppermost region of the pharynx or \

Wikipedia : 72 Nasopharynx cancer or nasopharyngeal carcinoma (NPC) is the most common cancer originating in the... more...

Related Diseases for Nasopharyngeal Carcinoma

Diseases in the Nasopharyngeal Carcinoma family:

Nasopharyngeal Carcinoma 3 Nasopharyngeal Carcinoma 2

Diseases related to Nasopharyngeal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
id Related Disease Score Top Affiliating Genes
1 lung cancer 29.2 BPIFA1 CASP3 CDH1 CDKN2A CYP2E1 EGFR
2 nasopharyngeal carcinoma 3 12.2
3 nasopharyngeal carcinoma 2 12.2
4 nasopharyngeal cancer, childhood 11.9
5 lymphoepithelioma-like carcinoma 11.3
6 nasopharyngitis 11.1
7 cervical adenoid cystic carcinoma 11.1 CDKN2A TP53
8 pediatric infratentorial ependymoma 11.1 EGFR TP53
9 multiple carboxylase deficiency 11.0 CDKN2A EGFR TP53
10 middle ear squamous cell carcinoma 11.0 CDKN2A EGFR TP53
11 secondary hyperparathyroidism of renal origin 11.0 CDKN2A EGFR TP53
12 molluscum contagiosum 11.0 CDKN2A EGFR TP53
13 lacrimal gland mucoepidermoid carcinoma 11.0 CDH1 EGFR TP53
14 gastrointestinal neuroendocrine tumor 11.0 CDH1 CDKN2A TP53
15 rare endometriosis 11.0 CDH1 CDKN2A TP53
16 orbital lymphoma 11.0 CDKN2A TP53 XRCC1
17 cecum adenocarcinoma 11.0 CDKN2A EGFR TP53
18 myxedema 11.0 CDKN2A EGFR TP53
19 renal pelvis urothelial papilloma 11.0 CDH1 TP53
20 schwannian stroma-rich and stroma-poor composite ganglioneuroblastoma 11.0 CDKN2A TP53 XRCC1
21 cystic lymphangioma 11.0 CDKN2A EGFR TP53
22 fallopian tube leiomyosarcoma 11.0 CDH1 CDKN2A TP53
23 dental caries 11.0 CDH1 NME1 TP53
24 ductal carcinoma in situ 11.0 CDH1 CDKN2A EGFR TP53
25 hodgkin's lymphoma, mixed cellularity 11.0 CDH1 CDKN2A TP53
26 nasal cavity disease 11.0 CDH1 NME1 TP53
27 anaerobic meningitis 11.0 EGFR HLA-A NME1
28 anaerobic pneumonia 11.0 CDH1 CDKN2A EGFR TP53
29 pancreatic somatostatinoma 11.0 CDH1 CDKN2A EGFR TP53
30 estrogen-receptor negative breast cancer 11.0 CDH1 CDKN2A EGFR TP53
31 periventricular nodular heterotopia 6 11.0 CDH1 CDKN2A EGFR TP53
32 cataract 24, anterior polar 11.0 CDH1 TP53 ZMYND10
33 paroxysmal nocturnal hemoglobinuria 11.0 CDH1 CDKN2A EGFR TP53
34 endometriosis of uterus 10.9 CDKN2A EGFR TP53
35 cleft lip palate dysmorphism kumar type 10.9 EGFR RASSF1 TP53
36 fallopian tube mucinous tumor 10.9 CDKN2A EGFR RASSF1 TP53
37 arteritic anterior ischemic optic neuropathy 10.9 CDH1 EGFR TP53
38 breast granular cell tumor 10.9 CDH1 EGFR NME1 TP53
39 tracheal disease 10.9 CASP3 CDH1 CDKN2A TP53
40 prostate transitional cell carcinoma 10.9 CASP3 CDH1 TP53
41 zimmermann-laband syndrome 2 10.9 CDH1 CDKN2A EGFR TP53
42 split hand split foot nystagmus 10.9 CDKN2A TP53
43 rhizomelic chondrodysplasia punctata, type 3 10.9 CASP3 TP53
44 ataxia-telangiectasia 10.9 CDKN2A NME1
45 mesothelioma, somatic 10.9 CDH1 CDKN2A RASSF1
46 benign shuddering attacks 10.9 CDH1 CDKN2A TP53
47 medullomyoblastoma 10.9 CASP3 CDH1 TP53
48 atrophic gastritis 10.9 CASP3 CDKN2A NME1 TP53
49 sertoli-leydig cell tumor 10.9 CDH1 CDKN2A EGFR MST1R TP53
50 apocrine adenocarcinoma 10.9 CDH1 EGFR TP53

Comorbidity relations with Nasopharyngeal Carcinoma via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Nasopharyngeal Carcinoma:



Diseases related to Nasopharyngeal Carcinoma

Symptoms & Phenotypes for Nasopharyngeal Carcinoma

Clinical features from OMIM:

607107

Human phenotypes related to Nasopharyngeal Carcinoma:

32
id Description HPO Frequency HPO Source Accession
1 neoplasia of the nasopharynx 32 HP:0100630

UMLS symptoms related to Nasopharyngeal Carcinoma:


headache, rhinorrhea

MGI Mouse Phenotypes related to Nasopharyngeal Carcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.91 CASP3 CDH1 CDKN2A EGFR MST1R NFKBIA
2 immune system MP:0005387 9.9 BPIFA1 CASP3 CDH1 CDKN2A EGFR MPP1
3 liver/biliary system MP:0005370 9.5 TP53 CDKN2A CYP2E1 EGFR MST1R NME1
4 neoplasm MP:0002006 9.28 RASSF1 TP53 XRCC1 CDH1 CDKN2A CYP2E1

Drugs & Therapeutics for Nasopharyngeal Carcinoma

Drugs for Nasopharyngeal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 322)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
3
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Docetaxel Approved May 1996, Investigational Phase 4,Phase 2,Phase 3,Phase 1 114977-28-5 148124 9877265
6 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
8 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
9 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
11 Autonomic Agents Phase 4,Phase 3,Phase 2
12 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antidepressive Agents Phase 4,Phase 3,Phase 2
14 Antidepressive Agents, Second-Generation Phase 4,Phase 2
15 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
16 Dopamine Agents Phase 4,Phase 2
17 Dopamine Uptake Inhibitors Phase 4,Phase 2
18 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
19 Central Nervous System Stimulants Phase 4,Phase 3
20 Cholinergic Agents Phase 4,Phase 3,Phase 2
21 Nicotinic Agonists Phase 4
22
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
23
Celecoxib Approved, Investigational Phase 3,Phase 2,Phase 1 169590-42-5 2662
24
Nedaplatin Approved Phase 3,Phase 1,Phase 2 95734-82-0
25
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
26
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
27
Epinephrine Approved, Vet_approved Phase 3,Phase 2 51-43-4 5816
28
Epirubicin Approved Phase 3,Phase 2,Phase 1 56420-45-2 41867
29 Racepinephrine Approved Phase 3,Phase 2
30
Amifostine Approved, Investigational Phase 3,Phase 1,Phase 2 20537-88-6 2141
31
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
32
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
33
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
34
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
35
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
36
Tegafur Approved Phase 3,Phase 2 17902-23-7 5386
37
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
38
Fluconazole Approved Phase 2, Phase 3 86386-73-4 3365
39
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
40
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
41
Megestrol acetate Approved, Vet_approved Phase 3 595-33-5 11683
42
Bleomycin Approved Phase 3 11056-06-7 5360373
43
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
44
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
45
Doxepin Approved Phase 3 1668-19-5 667477 667468
46
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
47
Pilocarpine Approved Phase 2, Phase 3 54-71-7, 92-13-7 5910
48
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
49
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
50
Aprepitant Approved, Investigational Phase 3,Phase 2 170729-80-3 151165 6918365

Interventional clinical trials:

(show top 50) (show all 529)

id Name Status NCT ID Phase Drugs
1 Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma Completed NCT00772681 Phase 4 docetaxel and cisplatin
2 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
3 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
4 Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma Recruiting NCT02293356 Phase 4 Nimotuzumab Injection
5 A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients Recruiting NCT02948699 Phase 4
6 Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury Recruiting NCT03069820 Phase 4 docetaxel and cisplatin
7 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
8 A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00705627 Phase 3 neoadjuvant chemotherapy plus concurrent chemoradiotherapy
9 The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma Unknown status NCT02537925 Phase 3 Celecoxib;Nedaplatin
10 Adjuvant Chemotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Unknown status NCT00677118 Phase 3 Cisplatin,fluorouracil;Cisplatin
11 Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma Unknown status NCT02089204 Phase 2, Phase 3
12 Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma Unknown status NCT01915134 Phase 3 Recombinant Human Endostatin plus gemcitabine and cisplatin;Gemcitabine and cisplatin
13 Efficacy Study of Neoadjuvant Chemotherapy With Chemoradiation Therapy for Nasopharyngeal Carcinoma Unknown status NCT01536223 Phase 3 PF (cisplatin and 5-fluorouracil) group;TPF (docetaxel plus cisplatin and 5-fluorouracil) group
14 Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Unknown status NCT01074021 Phase 3 Nimotuzumab;placebo plus chemoradiotherapy
15 Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma Unknown status NCT02301208 Phase 3 Nedaplatin;Cisplatin
16 Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC Unknown status NCT01854203 Phase 2, Phase 3 Inductive chemotherapy + concurrent cisplatin and IMRT;Inductive chemotherapy + IMRT
17 PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCIN Unknown status NCT00180973 Phase 3 Hydroxyurea
18 Radiation Therapy Alone Compared to Radiation Therapy Plus Chemotherapy in Treating Patients With Previously Untreated Cancer of the Nasopharynx Unknown status NCT00003637 Phase 3 cisplatin;fluorouracil
19 A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma Unknown status NCT02444949 Phase 3 endostar;cisplatin
20 Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer Unknown status NCT01689558 Phase 2, Phase 3 Recombine Endostatin
21 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
22 Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00002659 Phase 3 cisplatin-e therapeutic implant
23 Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma Completed NCT01540136 Phase 3 Nedaplatin;Cisplatin
24 Late-Course Accelerated Hyperfractionated IMRT for Locoregionally Advanced Nasopharyngeal Carcinoma Completed NCT00778908 Phase 2, Phase 3 Concomitant cisplatin chemotherapy
25 A Multicenter Trial Comparing Induction C/T Followed by CCRT v.s. CCRT Alone in Stage IV Nasopharyngeal Carcinoma Completed NCT00201396 Phase 3 Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin
26 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer Completed NCT00274937 Phase 3 amifostine trihydrate;fluorouracil;cisplatin
27 Phase III: Assess Conventional RT w/ Conventional Plus Accelerated Boost RT in the Treatment of Nasopharyngeal CA Completed NCT00535795 Phase 3
28 Low-level Laser Therapy to Prevent Oral Mucositis in Head and Neck Patients Completed NCT01439724 Phase 3
29 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
30 Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck Cancer Completed NCT00002507 Phase 3 mitomycin C;porfiromycin
31 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
32 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
33 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
34 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
35 Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx Completed NCT00004234 Phase 3
36 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
37 Radiation Therapy With or Without Chemotherapy in Treating Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
38 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
39 Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer Completed NCT00003592 Phase 3 methotrexate;paclitaxel
40 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
41 TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma Recruiting NCT02940925 Phase 3
42 Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02460419 Phase 3 capecitabine
43 Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT02958111 Phase 3 Capecitabine
44 The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT Recruiting NCT01817023 Phase 3 Cisplatin
45 Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma Recruiting NCT02111460 Phase 3
46 A Multicenter Trial Evaluating the Efficacy of Nedaplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Recruiting NCT01479504 Phase 3 nedaplatin and docetaxel;cisplatin and docetaxel;nedaplatin and docetaxel;cisplatin and docetaxel
47 Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma Recruiting NCT03015727 Phase 3 Docetaxel;Cisplatin;Chemotherapy
48 A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma Recruiting NCT02512315 Phase 3 Docetaxel (DOC);Cisplatin (DDP)
49 Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma Recruiting NCT02610010 Phase 3 Cisplatin
50 Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma Recruiting NCT02944708 Phase 3 Conventional chemotherapy;Maintenance chemotherapy 1;Maintenance chemotherapy 2

Search NIH Clinical Center for Nasopharyngeal Carcinoma

Cochrane evidence based reviews: nasopharyngeal neoplasms

Genetic Tests for Nasopharyngeal Carcinoma

Genetic tests related to Nasopharyngeal Carcinoma:

id Genetic test Affiliating Genes
1 Nasopharyngeal Carcinoma 29

Anatomical Context for Nasopharyngeal Carcinoma

MalaCards organs/tissues related to Nasopharyngeal Carcinoma:

39
Lung, Skin, Liver, Lymph Node, Brain, Breast, Endothelial

Publications for Nasopharyngeal Carcinoma

Articles related to Nasopharyngeal Carcinoma:

(show top 50) (show all 1583)
id Title Authors Year
1
Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma. ( 28351314 )
2017
2
(18)F-FLT and (18)F-FDG PET/CT in Predicting Response to Chemoradiotherapy in Nasopharyngeal Carcinoma: Preliminary Results. ( 28091565 )
2017
3
High expression of Ki-67 acts a poor prognosis indicator in locally advanced nasopharyngeal carcinoma. ( 28947213 )
2017
4
Minicircle-oriP-miR-31 as a Novel EBNA1-specific miRNA Therapy Approach for Nasopharyngeal Carcinoma. ( 28042945 )
2017
5
Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma. ( 28939083 )
2017
6
Effects of dosimetric inadequacy on local control and toxicities in the patients with T4 nasopharyngeal carcinoma extending into the intracranial space and treated with intensity-modulated radiotherapy plus chemotherapy. ( 28931426 )
2017
7
Long non-coding RNA PCAT7 regulates ELF2 signaling through inhibition of miR-134-5p in nasopharyngeal carcinoma. ( 28728844 )
2017
8
Dysregulated miR-27a-3p promotes nasopharyngeal carcinoma cell proliferation and migration by targeting Mapk10. ( 28393229 )
2017
9
Laminaria Japonica Polysaccharides effectively inhibited the growth of nasopharyngeal carcinoma cells in vivo and in vitro study. ( 28501488 )
2017
10
Knockdown of TKTL1 additively complements cisplatin-induced cytotoxicity in nasopharyngeal carcinoma cells by regulating the levels of NADPH and ribose-5-phosphate. ( 27916418 )
2017
11
Super-enhancers promote transcriptional dysregulation in nasopharyngeal carcinoma. ( 28951465 )
2017
12
Resveratrol enhances the radiosensitivity of nasopharyngeal carcinoma cells by downregulating E2F1. ( 28184930 )
2017
13
Efficacy and safety of nimotuzumab with neoadjuvant chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma. ( 28493838 )
2017
14
Low expression of nm23-H1 associates with poor survival of nasopharyngeal carcinoma patients: A prisma-compliant meta-analysis. ( 28614246 )
2017
15
Interaction between miR-572 and PPP2R2C and their effects on proliferation, migration and invasion of nasopharyngeal carcinoma (NPC) cells. ( 28525724 )
2017
16
BEX3 contributes to cisplatin chemoresistance in nasopharyngeal carcinoma. ( 28083995 )
2017
17
Therapeutic outcome of nasopharyngeal carcinoma with cranial nerve palsy: a single institution experience of 104 patients. ( 28435298 )
2017
18
Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study. ( 28532605 )
2017
19
CYP2E1 polymorphisms and nasopharyngeal carcinoma risk: a meta-analysis. ( 27491320 )
2017
20
Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells. ( 28496336 )
2017
21
Differences in Zbtb7a expression cause heterogeneous changes in human nasopharyngeal carcinoma CNE3 sublines. ( 28927029 )
2017
22
Who benefited most from higher cumulative dose of cisplatin among patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiation therapy? A retrospective study of 527 cases. ( 28928873 )
2017
23
Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. ( 28939063 )
2017
24
PKCI+ promotes local advancement via its dual roles in nasopharyngeal carcinoma. ( 28084179 )
2017
25
Dosimetric comparison and observation of three-dimensional conformal radiotherapy for recurrent nasopharyngeal carcinoma. ( 28943965 )
2017
26
Inactivation of HMGCL promotes proliferation and metastasis of nasopharyngeal carcinoma by suppressing oxidative stress. ( 28931870 )
2017
27
miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. ( 28315691 )
2017
28
SPINK6 Promotes Metastasis of Nasopharyngeal Carcinoma via Binding and Activation of Epithelial Growth Factor Receptor. ( 27671677 )
2017
29
Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress. ( 28078787 )
2017
30
Prognostic impact of pre-treatment neutrophil-to-lymphocyte ratio (NLR) in nasopharyngeal carcinoma: A retrospective study of 180 Taiwanese patients. ( 28950051 )
2017
31
The effects of recombinant human granulocyte colony-stimulating factor mouthwash on radiotherapy-induced oral mucositis in locally advanced nasopharyngeal carcinoma patients. ( 28791814 )
2017
32
Higher N stage and serum ferritin, but lower serum albumin levels are associated with distant metastasis and poor survival in patients with nasopharyngeal carcinoma following intensity-modulated radiotherapy. ( 28500850 )
2017
33
Long-Term Progression of Sensorineural Hearing Loss and Tinnitus after Combined Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy for Nasopharyngeal Carcinoma: A Case Report. ( 28878660 )
2017
34
miR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma. ( 28053597 )
2017
35
Influence of Cervical Node Necrosis of Different Grades on the Prognosis of Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy. ( 28529607 )
2017
36
Annexin A1 can inhibit the in vitro invasive ability of nasopharyngeal carcinoma cells possibly through Annexin A1/S100A9/Vimentin interaction. ( 28355254 )
2017
37
Intensity-modulated radiotherapy provides better quality of life than two-dimensional conventional radiotherapy for patients with stage II nasopharyngeal carcinoma. ( 28515352 )
2017
38
Oncogenic S1P signalling in EBV-associated nasopharyngeal carcinoma activates AKT and promotes cell migration through S1P receptor 3. ( 28240350 )
2017
39
Epstein-Barr virus-encoded LMP2A stimulates migration of nasopharyngeal carcinoma cells via EGFR/Ca(2+)/calpain/ITGI^4 axis. ( 28512118 )
2017
40
Nasopharyngeal carcinoma treated with bevacizumab combined with paclitaxel liposome plus cisplatin: a case report and literature review. ( 28053541 )
2017
41
Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma. ( 28061788 )
2017
42
Histogram analysis of diffusion kurtosis imaging of nasopharyngeal carcinoma: Correlation between quantitative parameters and clinical stage. ( 28525383 )
2017
43
Epigallocatechin-3-gallate Modulates MicroRNA Expression Profiles in Human Nasopharyngeal Carcinoma CNE2 Cells. ( 28051030 )
2017
44
Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? ( 28529609 )
2017
45
Prognostic value of cervical nodal tumor volume in nasopharyngeal carcinoma: Analysis of 1230 patients with positive cervical nodal metastasis. ( 28489930 )
2017
46
Long non-coding RNA LOC100129148 functions as an oncogene in human nasopharyngeal carcinoma by targeting miR-539-5p. ( 28328537 )
2017
47
MiR-183 overexpression inhibits tumorigenesis and enhances DDP-induced cytotoxicity by targeting MTA1 in nasopharyngeal carcinoma. ( 28631568 )
2017
48
A large-scale retrospective study of the overall survival outcome in nasopharyngeal carcinoma with hypertension in Chinese population. ( 28498819 )
2017
49
Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. ( 27923823 )
2017
50
MicroRNA-212 inhibits the metastasis of nasopharyngeal carcinoma by targeting SOX4. ( 28504814 )
2017

Variations for Nasopharyngeal Carcinoma

ClinVar genetic disease variations for Nasopharyngeal Carcinoma:

6 (show all 16)
id Gene Variation Type Significance SNP ID Assembly Location
1 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
2 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
3 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
5 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
6 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
7 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
8 NRAS NM_002524.4(NRAS): c.181C> A (p.Gln61Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913254 GRCh37 Chromosome 1, 115256530: 115256530
9 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
10 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
11 TP53 NM_000546.5(TP53): c.638G> C (p.Arg213Pro) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh37 Chromosome 17, 7578211: 7578211
12 NRAS NM_002524.4(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
13 NRAS NM_002524.4(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs121913255 GRCh38 Chromosome 1, 114713907: 114713907
14 NRAS NM_002524.4(NRAS): c.182A> T (p.Gln61Leu) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
15 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
16 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407

Cosmic variations for Nasopharyngeal Carcinoma:

9 (show top 50) (show all 605)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM2255920 ZNF609 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1984G>A p.A662T 13
2 COSM4995216 ZC3H13 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.44C>G p.T15S 13
3 COSM4995307 ZBTB17 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.281C>T p.A94V 13
4 COSM4995092 VPS33A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.221C>A p.A74D 13
5 COSM4996600 VNN2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.83C>A p.A28D 13
6 COSM4995249 VANGL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.884T>C p.L295P 13
7 COSM4996245 USP34 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5131C>T p.Q1711* 13
8 COSM4997193 USP19 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3636G>T p.L1212F 13
9 COSM4995369 USH2A upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.89T>C p.L30S 13
10 COSM2978223 USH1G upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.520G>A p.D174N 13
11 COSM4995852 USE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.370G>T p.E124* 13
12 COSM4996719 TTBK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1757G>A p.R586Q 13
13 COSM4997149 TSR2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.187G>C p.D63H 13
14 COSM1524842 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1783G>A p.D595N 13
15 COSM4995873 TSHZ3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1121C>T p.P374L 13
16 COSM4995721 TRAF4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.955C>G p.R319G 13
17 COSM2123037 TPR upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3879G>A p.M1293I 13
18 COSM4996315 TP63 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1413C>G p.S471R 13
19 COSM10654 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.637C>T p.R213* 13
20 COSM10724 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.839G>C p.R280T 13
21 COSM43906 TP53 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.843C>A p.D281E 13
22 COSM1739496 TNKS upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.583G>A p.V195M 13
23 COSM4996454 TMPRSS11E upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.268G>T p.A90S 13
24 COSM4996730 TFAP2D upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.767C>A p.A256E 13
25 COSM4996391 TET2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.4250T>G p.V1417G 13
26 COSM4996386 TET2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.988G>C p.E330Q 13
27 COSM4996526 SYNPO upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1394C>A p.P465Q 13
28 COSM4996648 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.6506C>T p.T2169I 13
29 COSM4996618 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.21845G>C p.W7282S 13
30 COSM4996643 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.7996C>A p.Q2666K 13
31 COSM4996638 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.8339T>C p.L2780P 13
32 COSM4996653 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.5827G>A p.E1943K 13
33 COSM4996628 SYNE1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.14707G>T p.V4903L 13
34 COSM191830 SPTBN1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1916G>A p.R639H 13
35 COSM4995726 SPACA3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.376A>G p.N126D 13
36 COSM4994835 SORCS3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3082G>A p.V1028I 13
37 COSM4995636 SMG1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1682A>G p.Y561C 13
38 COSM2128623 SMG1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2699A>G p.N900S 13
39 COSM4996349 SMARCC1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2927G>C p.G976A 13
40 COSM4997191 SLITRK3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.796C>T p.H266Y 13
41 COSM4996929 SLC7A2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.296C>A p.A99E 13
42 COSM4996458 SLC4A4 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.331C>G p.L111V 13
43 COSM4997189 SLC19A1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.758G>T p.R253L 13
44 COSM4994897 SIRT1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.568C>A p.Q190K 13
45 COSM4995400 SIPA1L2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2574C>A p.H858Q 13
46 COSM2167722 SF3A3 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.1081G>A p.E361K 13
47 COSM4996346 SETD2 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.3808C>T p.R1270C 13
48 COSM4996834 SDK1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.6347T>G p.L2116R 13
49 COSM971349 SALL1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.2582C>T p.S861L 13
50 COSM1332064 S1PR1 upper aerodigestive tract,pharynx,carcinoma,nasopharyngeal carcinoma c.424C>T p.R142C 13

Copy number variations for Nasopharyngeal Carcinoma from CNVD:

7 (show all 41)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 72234 12 7764270 8036678 Duplication CLEC4C Nasopharyngeal cancer
2 72235 12 7764270 8036678 Duplication NANOG Nasopharyngeal cancer
3 72236 12 7764270 8036678 Duplication NANOGNB Nasopharyngeal cancer
4 72237 12 7764270 8036678 Duplication SLC2A14 Nasopharyngeal cancer
5 72238 12 7764270 8036678 Duplication SLC2A3 Nasopharyngeal cancer
6 126614 19 19848080 20497256 Deletion MIR1270-1 Nasopharyngeal cancer
7 126615 19 19848080 20497256 Deletion MIR1270-2 Nasopharyngeal cancer
8 126616 19 19848080 20497256 Deletion ZNF253 Nasopharyngeal cancer
9 126617 19 19848080 20497256 Deletion ZNF486 Nasopharyngeal cancer
10 126618 19 19848080 20497256 Deletion ZNF682 Nasopharyngeal cancer
11 126619 19 19848080 20497256 Deletion ZNF826P Nasopharyngeal cancer
12 126620 19 19848080 20497256 Deletion ZNF90 Nasopharyngeal cancer
13 126621 19 19848080 20497256 Deletion ZNF93 Nasopharyngeal cancer
14 132647 19 59423491 59445355 Deletion LILRA6 Nasopharyngeal cancer
15 171484 3 168801287 168851758 Amplification EVI1 Nasopharyngeal cancer
16 171493 3 168867391 169381563 Amplification MDS1 Nasopharyngeal cancer
17 177937 3 65166887 65190844 Deletion Nasopharyngeal cancer
18 197433 5 176843000 176857208 Deletion LMP1 Nasopharyngeal cancer
19 205127 6 121025447 121050579 Deletion Nasopharyngeal cancer
20 210827 6 31463047 31563588 Deletion HCG26 Nasopharyngeal cancer
21 210828 6 31463047 31563588 Deletion HCP5 Nasopharyngeal cancer
22 210829 6 31463047 31563588 Deletion MICA Nasopharyngeal cancer
23 210832 6 31463297 31559455 Deletion HCG26 Nasopharyngeal cancer
24 210836 6 31463297 31559455 Deletion HCP5 Nasopharyngeal cancer
25 210840 6 31463297 31559455 Deletion MICA Nasopharyngeal cancer
26 212636 6 4007991 32935606 Deletion LMP2 Nasopharyngeal cancer
27 220654 7 140736 180194 Duplication CCDC146 Nasopharyngeal cancer
28 220655 7 140736 180194 Duplication LOC100132832 Nasopharyngeal cancer
29 220656 7 140736 180194 Duplication LOC100133091 Nasopharyngeal cancer
30 220657 7 140736 180194 Duplication PMS2L11 Nasopharyngeal cancer
31 220658 7 140736 180194 Duplication POMZP3 Nasopharyngeal cancer
32 222456 7 152200000 154700000 Duplication Nasopharyngeal cancer
33 222457 7 152200000 154700000 Duplication Nasopharyngeal cancer
34 222532 7 153118877 153284978 Duplication Nasopharyngeal cancer
35 222533 7 153118877 153284978 Duplication Nasopharyngeal cancer
36 224029 7 2721151 3758564 Duplication CARD11 Nasopharyngeal cancer
37 224030 7 2721151 3758564 Duplication GNA12 Nasopharyngeal cancer
38 227304 7 66680598 66860844 Deletion AR Nasopharyngeal cancer
39 229234 7 892539 3753994 Duplication Nasopharyngeal cancer
40 236340 8 15447307 15475846 Deletion TUSC3 Nasopharyngeal cancer
41 256863 9 9780222 9786577 Deletion Nasopharyngeal cancer

Expression for Nasopharyngeal Carcinoma

Search GEO for disease gene expression data for Nasopharyngeal Carcinoma.

Pathways for Nasopharyngeal Carcinoma

Pathways related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

(show all 17)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 CASP3 CDH1 CDKN2A EGFR NFKBIA RASSF1
2
Show member pathways
12.28 CASP3 EGFR NFKBIA TP53
3 12.25 CDKN2A HLA-A NFKBIA TP53
4 12.24 CASP3 CDKN2A EGFR RASSF1 TP53
5
Show member pathways
12.15 CASP3 CDH1 EGFR NFKBIA TP53
6 12.1 CASP3 CDH1 CDKN2A EGFR NFKBIA RASSF1
7 11.98 CASP3 CDH1 EGFR TP53
8 11.92 CASP3 CDH1 EGFR TP53
9 11.86 CASP3 CDKN2A HLA-A NFKBIA TP53
10 11.67 CASP3 NFKBIA TP53
11 11.56 CASP3 CDKN2A TP53
12 11.51 CASP3 EGFR NFKBIA
13 11.48 CASP3 EGFR NFKBIA
14 11.36 CDKN2A EGFR TP53
15 10.99 CDH1 EGFR MST1R
16 10.88 CDH1 CDKN2A EGFR RASSF1 TP53
17 10.69 CASP3 EGFR

GO Terms for Nasopharyngeal Carcinoma

Biological processes related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to organic substance GO:0010033 9.54 CASP3 CDH1 XRCC1
2 Ras protein signal transduction GO:0007265 9.43 CDKN2A RASSF1 TP53
3 cellular response to drug GO:0035690 9.33 EGFR NME1 TP53
4 replicative senescence GO:0090399 9.32 CDKN2A TP53
5 hippocampus development GO:0021766 9.13 CASP3 NME1 XRCC1
6 response to drug GO:0042493 8.92 CASP3 CDH1 CYP2E1 XRCC1

Molecular functions related to Nasopharyngeal Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 BPIFA1 CASP3 CDH1 CDKN2A EGFR HLA-A
2 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 9.16 CASP3 CDKN2A
3 enzyme binding GO:0019899 9.1 CYP2E1 EGFR MST1R NFKBIA TP53 XRCC1

Sources for Nasopharyngeal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....